Acrivon Therapeutics Inc. Common Stock (ACRV)
Stock · NASDAQ · Health Care
$1.65as of 10/16/2026
Price chart
Active signals
ACRV Signal Track Record
How signals performed across all stocks →What ACRV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -10.4% | 35% | September 11, 2026 |
| Bollinger Band Breakout | 16 | -6.7% | 44% | August 14, 2026 |
| Bollinger Band BreakdownActive now | 13 | -9.7% | 46% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -2.9% | 38% | September 15, 2026 |
| Any 20-session window (baseline) | -3.0% | 45% |
Computed by MarketWall from daily closing prices since September 1, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACRV
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature c…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 74
- Website
- acrivon.com/
Fundamentals
- 1-day range
- $1.63$1.77
- Market cap
- $72.33M
- P/E (trailing)
- —
- P/E (forward)
- -1.00
- EPS (trailing)
- $-1.88
- Dividend yield
- —
- Beta
- 1.95
- Avg. volume
- 318.2K
Forecasts
6 analyst ratings
Acrivon Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ACRVAcrivon Therapeutics Inc. Common Stock$1.64▼ 6.82%Market cap $72.33MP/E —$1.27$3.56
- ELTXElicio Therapeutics Inc. Common Stock$1.56▼ 12.36%Market cap $72.28MP/E —$1.71$16
- CYPHCypherpunk Technologies Inc. Common Stock$2.57▼ 14.90%Market cap $71.74MP/E —$0.393$4.19
- SPROSpero Therapeutics Inc. Common Stock$1.1▼ 2.65%Market cap $73.53MP/E 8.91$1.08$3.08
- CTORCitius Oncology Inc. Common Stock$0.768▲ 2.95%Market cap $70.67MP/E —$0.491$2.25
- ACETAdicet Bio Inc. Common Stock$4.57▼ 11.09%Market cap $74.13MP/E —$4.8$17.04
- TLPHTalphera Inc. Common Stock$1.08▲ 0.93%Market cap $74.22MP/E —$0.6866$1.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $1.64 | ▼ 6.82% | $1.27$3.56 |
| ELTX Elicio Therapeutics Inc. Common Stock | $72.28M | — | $1.56 | ▼ 12.36% | $1.71$16 |
| CYPH Cypherpunk Technologies Inc. Common Stock | $71.74M | — | $2.57 | ▼ 14.90% | $0.393$4.19 |
| SPRO Spero Therapeutics Inc. Common Stock | $73.53M | 8.91 | $1.1 | ▼ 2.65% | $1.08$3.08 |
| CTOR Citius Oncology Inc. Common Stock | $70.67M | — | $0.768 | ▲ 2.95% | $0.491$2.25 |
| ACET Adicet Bio Inc. Common Stock | $74.13M | — | $4.57 | ▼ 11.09% | $4.8$17.04 |
| TLPH Talphera Inc. Common Stock | $74.22M | — | $1.08 | ▲ 0.93% | $0.6866$1.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy StockYahoo · 9/15/2026
Insider Activity
Insider Actions →- Mary Miller · October 5, 2026 · Sale294 @ $1.99
- Levin Michaela · August 31, 2026 · Grant130.0K
- Levin Michaela · August 31, 2026 · Grant30.0K
- Peter Blume-Jensen · August 25, 2026 · Sale14.0K @ $2.21
- Katharine Peterson · August 18, 2026 · Sale101 @ $2.01
- Mary Miller · August 18, 2026 · Sale185 @ $2.01
- Erick Gamelin · August 18, 2026 · Sale400 @ $2.01
- Eric Devroe · August 18, 2026 · Sale604 @ $2.01
- Peter Blume-Jensen · August 18, 2026 · Sale484 @ $2.01
- Peter Blume-Jensen · August 18, 2026 · Sale1.2K @ $2.01
- Adam D. Levy · August 4, 2026 · Sale1.1K @ $1.57
- Mary Miller · July 21, 2026 · Sale573 @ $1.76
- Santhosh Palani · June 17, 2026 · Grant20.3K
- Derek DiRocco · June 17, 2026 · Grant20.3K
- Sharon Shacham · June 17, 2026 · Grant20.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 16.12M
- Total value held
- $20.98M
- Institutional holders
- 41
- Unknown8.34M
- Unknown2.12M
- Unknown888.1K
- Unknown846.0K
- Unknown758.4K
- Unknown722.0K
- Unknown560.4K
- Unknown389.4K
- Unknown239.7K
- Unknown236.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Acrivon Therapeutics noted among health‑care stocks moving in after‑market
Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.
Acrivon Therapeutics noted among health‑care stocks moving in after‑market. Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.